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Abstract
Background: Klebsiella pneumoniae as an opportunistic pathogen can be the cause of a range of nosocomial and community - ac-
quired infections. Many virulence factors help these bacteria overcome an immune system and cause various diseases. K1 and K2
capsular antigens, also magA, wcaG, and rmpA are well - known K. pneumoniae virulence factors. Klebsiella pneumoniae has been re-
vealed to have the ability to acquire resistance to many antibiotics, which cause treatment failure.
Objectives: This study aimed at determining the prevalence of magA, wcaG, rmpA, Capsular type K1, Capsular type K2, TEM, and SHV
in K. pneumoniae isolates.
Methods: A total of 173 non - duplicate K. pneumoniae isolates were collected from two different hospitals in Semnan, Iran, from urine
specimens. Klebsiella pneumoniae was identified by conventional bacteriological tests. Disk diffusion test was performed according
to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). Detection of virulence factors, TEM, and SHV gene was
performed by specific primers.
Results: Frequency of virulence factors was as follow: capsular type K2: 32.9%, rmpA: 20.2%, capsular type K1: 6.9%, and wcaG: 16.2%.
Also, the SHV and TEM were observed in 46.8% and 33.5%, respectively. Antibiotics resistance rates were as follow, imipenem: 7.5%,
ciprofloxacin: 16.1%, levofloxacin: 17.3%, amoxicillin - clavulanic acid: 30%, trimethoprim - sulfamethoxazole: 32.9%, cefepime: 34.1%,
nitrofurantoin: 35.8%, amikacin: 36.4%, aztreonam: 39.3%, ceftazidime: 42.7%.
Conclusions: Frequency of some virulence factors including capsular type K2, rmpA, wcaG, and also resistant rate to imipenem,
amikacin, and ceftazidime were significantly higher than similar studies. Presence of virulence factors accompanied by drug resis-
tance should make bacteria an infectious agent and lead to treatment failure.
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1. Background
Klebsiella pneumoniae, as an opportunistic pathogen,
can be the cause of a range of nosocomial and commu-
nity - acquired infections (1-3). Pathogenic K. pneumoniae
strains are responsible for urinary tract, respiratory, and
blood infections and are associated with mortality and
morbidity in patients (4-6). Pathogenicity of K. pneumo-
niae is the result of production of many virulence factors
that help these bacteria overcome the immune system and
cause various diseases. Different virulence factors, such as
lipopolysaccharide (o - antigen), capsular polysaccharides
(K antigen), fimbriae and siderophores contribute to the
pathogenicity of Klebsiella (7, 8). Among these factors, the
capsule is one of the most important virulence determi-
nants, which helps achieve biofilm formation and leads to
protection against phagocytosis, antimicrobial peptides,
and serum bactericidal activity. There are more than 77
types of capsular antigens in K. pneumoniae strains, of
which K1 and K2 serotypes are well known (9, 10).
Klebsiella pneumoniae also carries virulence - associated
genes, which may encode capsules (magA, K2A, WcaG) and
a capsular regulator gene (regulator of mucoid pheno-
type (rmpA). Mucoviscosity - associated gene A (magA) and
WcGA genes located within the gene clusters are responsi-
ble for encoding capsular polymerase and capsular biosyn-
thesis, respectively (11-13). Capsular biogenesis by magA is
achieved through conversion of manose to fucose, which
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may enhance the ability of the bacteria to evade phagocy-
tosis by macrophage. The regulator of mucoid phenotype
A (rmpA) gene located on the plasmid increases capsular
polysaccharide production and is found in the hypermu-
coviscous phenotype. Moreover, two genes, including the
magA and rmpA, were initially associated with invasive in-
fections (14, 15).
Resistance of pathogenic bacteria to different antibi-
otics has become a serious worldwide problem because
of the fatal outcome of defective treatment and the dif-
ficulty to find treatment options (16). Klebsiella pneumo-
niae has been revealed to have the ability to acquire re-
sistance to many antibiotics, especially third generation
cephalosporins. Multidrug resistance of K. pneumoniae
against the antibiotics used for therapy intensifies the vir-
ulence potential of Klebsiella. Beta - lactam antibiotics are
one of the most commonly used antibiotics in the treat-
ment of bacterial infections and the production of B - lacta-
mase enzymes are the most common bacterial resistance
mechanisms (17, 18). In the recent years, Extended Spec-
trum Beta Lactamase (ESBL) producer K. pneumoniae have
increased over the world. The ESBLs are divided to several
groups; the main groups are TEM, CTX, and SHV derivatives
(19, 20).
2. Objectives
The present study aimed at determining the preva-
lence of magA, wcaG, rmpA, Capsular type K1 and Capsular
type K2 virulence genes along with SHV and TEM beta lac-
tam resistance genes in K. pneumoniae isolates.
3. Methods
3.1. Ethics Statement
The ethics committee of the Semnan University of
Medical Sciences, Semnan, Iran, approved this study
(IR.SEMUMS.REC 1394.29).
3.2. Sampling
A cross sectional study was performed. A total of 173
non - duplicate K. pneumoniae isolates were collected dur-
ing year 2015 at two different hospitals of Semnan, Iran,
from urine specimens.
3.3. Bacterial Identification
The specimens were cultured on blood agar and Eosin
Methylene Blue (EMB) agar (Merck, Darmstadt, Germany),
and incubated at 37°C for 24 hours. Klebsiella pneumoniae
was identified by conventional bacteriological tests. Gram
stain was performed for suspected colonies. Biochemi-
cal tests, including lactose fermentation, gas production
from glucose, FeS production, motility, indole production,
sodium citrate utilization, and urea utilization were used
for K. pneumoniae identification (21).
3.4. Antibiotic Susceptibility Testing
Disks diffusion test was performed according to the
guidelines of the Clinical and Laboratory Standards In-
stitute (22). Used disks (Rosco, Taastrup, Denmark) were
amikacin (30 µg), ciprofloxacin (5 µg), amoxicillin - clavu-
lanic acid (20/10 µg), ceftazidime (30 µg), imipenem (10
µg), cefepime (30 µg), aztreonam (30 µg), nitrofurantoin
(300 µg), and trimethoprim - sulfamethoxazole (1.25/23.75
µg). Escherichia coli (ATCC 25922) strain was used for qual-
ity control.
3.5. DNA Extraction
DNA of each K. pneumoniae isolate was extracted from
1 mL of overnight bacterial culture. Extraction was per-
formed as previously described by Kuske et al. (23). The su-
pernatant was used as the template DNA in PCR reactions.
3.6. Detection of Capsular type K1, Capsular type K2, rmpA,
wcaG, TEM, and SHV
Specific primers for detection of Capsular type K1, Cap-
sular type K2, rmpA, wcaG, TEM, and SHV are shown in Ta-
ble 1. For capsular type K1, capsular type K2, rmpA, and
wcaG amplification were performed as follow: initial de-
naturation at 95°C for five minutes, followed by 35 cycles
at 94°C for 30 seconds, 58°C for 90 seconds and 72°C for 90
seconds and a final extension at 72°C for 10 minutes (24).
Polymerase Chain Reaction (PCR) conditions for TEM am-
plification were as follow: initial denaturation at 94°C for
three minutes, 35 cycles at 94°C for 30 seconds, 45°C for one
minute, 72°C for one minute, final extension at 72°C for 10
minutes (25). The SHV was amplified under the following
conditions: 94°C for three minutes, 35 cycles at 94°C for 30
minutes, 60°C for one minute, 72°C for one minute, and a
final extension at 72°C for 10 minutes (25). The PCR prod-
ucts were analyzed by electrophoresis with 1% agarose gel
in 1X Tris - Acetate - EDTA buffer. The gels were stained with
ethidium bromide and the PCR products were visualized
under UV light (Figure 1).
3.7. Statistical Analysis
Confidence interval test was used to assess the statisti-
cal significance with confidence level of 95% (α = 0.05).
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Table 1. Specific Primers for Detection of Capsular Type K1, Capsular Type K2, rmpA, wcaG, TEM, and SHV
Gene Primer Sequence Product Size (bp) Reference
Capsular type K1 MagA - F GGTGCTCTTTACATCATTGC 1283 Turton et al. (24)
MagA - R GCAATGGCCATTTGCGTTAG
Capsular type K2 K2wzy - F GACCCGATATTCATACTTGACAGAG 641 Turton et al. (24)
K2wzy - R CCTGAAGTAAAATCGTAAATAGATGGC
rmpA rmpA - F ACTGGGCTACCTCTGCTTCA 516 Turton et al. (24)
rmpA - R CTTGCATGAGCCATCTTTCA
wcaG wcaG - F GGTTGGKTCAGCAATCGTA 169 Turton et al. (24)
wcaG - R ACTATTCCGCCAACTTTTGC
SHV SHV - F AAGATCCACTATCGCCCAGCAG 200 Shahcheraghi et al. (25)
SHV - R ATTCAGTTCCGTTTCCCAGCGG
TEM TEM - F GAGTATTCAACATTTCCGTGTC 800 Shahcheraghi et al. (25)
TEM - R TAATCAGTGAGGCACCTATCTC
Figure 1. PCR products electrophoresis. 1: Marker (100 bp), 2: Capsular type K1 (1283
bp), 3: wcaG (169 bp), 4: Capsular type K2 (641 bp), 5: SHV (200 bp), 6: TEM (800bp),
7:rmp A (516 bp), 8: negative control.
4. Results
In this study, frequency of virulence factors was as fol-
low: capsular type K2: 57 out of 173 (32.9% CI: 39.9%, 25.9%),
rmpA: 35 out of 173 (20.2% CI: 26.2%, 14.2%), wcaG: 28 out
of 173 (16.2% CI: 19.4%, 13%), capsular type K1: 12 out of 173
(6.9% CI: 10.6%, 3.2%). Also, the SHV was observed in 81 out
of 173 (46.8% CI: 51.2%, 42.4%) and TEM was observed in 58
out of 173 (33.5% CI: 37.5%, 29.5%) cases. The resistant rates
to antibiotics were as follow, imipenem: 13 out of 173 (7.5%
CI: 9.8%, 5.2%), ciprofloxacin: 28 out of 173 (16.1% CI: 19.2%,
13%), amoxicillin - clavulanic acid: 52 out of 173 (30% CI:
33.9%, 26.1%), trimethoprim - sulfamethoxazole: 57 out of
173 (32.9% CI: 36.9%, 28.9%), cefepime: 59 out of 173 (34.1%
CI: 38.2%, 30%), nitrfurantoin: 62 out of 173 (35.8% CI: 35.8%,
27.8%), amikacin: 63 out of 173 (36.4% CI: 40.5%, 32.3%), aztre-
onam: 68 out of 173 (39.3% CI: 43.5%, 35.1%).
5. Discussion
Klebsiella pneumoniae is the cause of nosocomial and
community acquired infections, such as urinary tract, res-
piratory, and blood infections. It harbors many virulence-
associated genes including magA, rmpA, WcaG, fimbriae,
and siderophores, which help the bacteria overcome the
immune system and cause infection. Drug resistant, espe-
cially ESBL - producing K. pneumoniae strains, contribute to
treatment failure and increase morbidity and mortality in
patients (26-28).
In this study, the frequency of SHV was significantly
lower than 69.6% and 67.4% reported by Shahcheraghi et
al. (25) and Feizabadi et al. (29), respectively. Frequency
of TEM was significantly lower than 54%, reported by Feiz-
abadi et al. (29), yet in accordance with 32.1% reported by
Shahcheraghi et al. (25). These differences were the re-
sult of differences in infection control system and ther-
apeutic regimens in different parts of Iran. Age of over
60, long hospitalization, diabetes and previous antibiotic
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treatment were other factors associated with the ESBL phe-
notype (30).
Capsular type K1 frequency was significantly lower
than 39.5% and 64.3% reported by Liu et al. (31) and Lee et al.
(32), yet significantly higher than 1.4% reported by Maatal-
lah et al. (33). Capsular type K2 frequency was significantly
higher than 18.4% and 20% reported by Liu et al. (30) and
Lee et al. (32), yet significantly lower than 5% reported by
Maatallah et al. (33). Frequency of rmpA was significantly
higher than 5.5%, 3.6%, and 7.0% reported by Derakhshan
et al. (27), Maatallah et al. (33), and Derakhshan et al., re-
spectively (34). Frequency of wcaG was significantly higher
than 2.7% and 8.6% reported by Derakhshan et al. (27) and
Maatallah et al. (33), yet significantly lower than 23.5% re-
ported by Derakhshan et al. (34).
The resistance rate to imipenem was significantly
higher than 1.4% and 0.05% reported by Liu et al. (31), and
Derakhshan et al. (34), and also reports of Shahcheraghi et
al. (25), Peerayeh et al. (26), Derakhshan et al. (27), Peer-
ayeh et al. (28), and Ranjbar et al. (35), which reported
no resistance to imipenem, yet significantly lower than
20.8% reported by Amraie et al. (36). The resistance rate
to ciprofloxacin was significantly lower than 44.4%, 37.1%,
42.5%, and 52.5% reported by Derakhshan et al. (27), Liu et
al. (31), Derakhshan et al. (34), and Ranjbar et al. (35), yet in
accordance with 18%, 18%, and 15.6% reported by Shahcher-
aghi et al. (25), Peerayeh et al. (26), and Amraie et al. (36).
The resistance rate to amoxicillin - clavulanic acid was sig-
nificantly lower than 31.7% and 28.6% reported by Liu et al.
(31) and Pereira et al. (37), yet in accordance with 100% and
60.5% reported by Derakhshan et al. (27) and Derakhshan
et al. (34), respectively.
The resistance rate to nitrofurantoin was significantly
lower than 40% and 71% reported by Ranjbar et al. (35) and
Amraie et al. (36). The resistance rate to trimethoprim -
sulfamethoxazole was significantly lower than 39%, 55.5%,
39.3%, 50%, 51.5%, and 54% reported by Peerayeh et al. (26),
Derakhshan et al. (27), Peerayeh et al. (26), Derakhshan
et al. (34), Ranjbar et al. (35), and Amraie et al. (36), re-
spectively, yet in accordance with 32.9% reported by Liu et
al. (31). The resistance rate to cefepime was significantly
higher than 12.9% reported by Liu et al. (31), yet in accor-
dance with 37.5% reported by Peerayeh et al. (26), also sig-
nificantly lower than 80.5% and 57% reported by Peerayeh
et al. (26) and Derakhshan et al. (34).
The resistance rate to amikacin was significantly
higher than 14%, 27%, 10%, 22%, and 4.8% reported by
Shahcheraghi et al. (25), Peerayeh et al. (26), Liu et al. (31),
Amraie et al. (36), and Pereira et al. (37), yet in accordance
with 31.5% reported by Derakhshan et al. (34), also signifi-
cantly lower than 50% reported by Derakhshan et al. (27).
The resistant rate to aztreonam was significantly lower
than 100%, 59%, and 92.5% reported by Derakhshan et al.
(27), Derakhshan et al. (34), and Ranjbar et al. (35), yet in
accordance with 39% and 38.1% reported by Peerayeh et
al. (26) and Pereira et al. (37), also, significantly higher
than 30% reported by Liu et al. (31). The resistance rate to
ceftazidime was significantly higher than 31.3%, 51.1%, 35.8%,
and 4.8% reported by Shahcheraghi et al. (25), Peerayeh
et al. (28), Liu et al. (31), and Pereira et al. (37), yet signifi-
cantly lower than 100%, 57%, 100%, and 49.7% reported by
Derakhshan et al. (27), Derakhshan et al. (34), and Ranjbar
et al. (35).
6. Conclusions
Frequency of some virulence factors including Cap-
sular type K2, rmpA, wcaG, and also resistance rates to
imipenem, amikacin, and ceftazidime were significantly
higher than similar studies. Presence of virulence factors
accompanied by drug resistance make bacteria an infec-
tious agent and lead to treatment failure.
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